Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | BCR | P11274 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134911 | 0.85 | PTGDR2 (0.37) | GRM5PDGFRBKDRPTGES | |
| SCHEMBL6133204 | 0.84 | ABL1 (0.48) | GRM5ABL1 | |
| SCHEMBL6134123 | 0.81 | GRM5 (0.52) | GRM5ABL1 | |
| SCHEMBL6133993 | 0.75 | FFAR1 (0.36) | GRM5ABL1PTGESFFAR1 | |
| SCHEMBL30873473 | 0.72 | GRM5 (0.58) | GRM5PTGESFFAR1PTPN1TSHR | |
| SCHEMBL6133285 | 0.70 | GRM5 (0.43) | GRM5KDRABL1 | |
| SCHEMBL6134347 | 0.68 | BMPR1B (0.30) | — | |
| SCHEMBL6133926 | 0.68 | NPSR1 (0.44) | TSHR | |
| SCHEMBL4714641 | 0.68 | GRM5 (0.64) | GRM5 | |
| SCHEMBL6134284 | 0.68 | GRM5 (0.51) | GRM5ABL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | GRM5 270/4885PDGFRB 269/4885KDR 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.